Montreal, April 9, 2015 – NEOMED announced today the appointment of two new members to its Board of Directors. Joining the board are Dr. Laurence Rulleau, Principal at CTI Life Sciences, and Mr. Paul Buron, Executive Vice President and Chief Financial Officer of the Business Development Bank of Canada (BDC).

Dr. Laurence Rulleau currently serves as Principal at CTI Life Sciences, a Montreal-based life sciences venture capital firm. Prior to joining CTI, she served as a life sciences analyst covering the Canadian life sciences sector for more than 10 years. She worked at different firms including Desjardins Securities, Yorkton Securities, and Blackmont Securities. She was involved in numerous mergers and acquisitions as well as IPOs. More recently she served as Vice-President Business Development of Univalor, the technology transfer office of Montreal’s university and affiliated schools. Under her responsibility at Univalor in the last three years, more than 40 licences with the industry were signed and eight companies started. Dr. Rulleau has a Masters in Biology from Université du Quebec à Montreal (UQAM) and a PhD from Université de Montréal executed at the Montreal Clinical Research Institute.

“I am extremely pleased to announce the appointment of Paul and Laurence to our Board of Directors. The addition of two such qualified professionals to our ranks will help us as we continue to work to bring innovative approaches to support the growth and success of the Canadian life sciences ecosystem. Both Laurence and Paul bring a long history of personal success, significant business acumen, and professional networks that will bring great value to the continued evolution and strategic direction of NEOMED,” said Donald Olds, Chairman of NEOMED’s Board of Directors. “On behalf of the entire board and NEOMED’s management, I am very pleased to welcome them as directors and look forward to benefiting from their valuable perspectives,” he added.

NEOMED is governed by an independent Board of Directors, composed of representatives from the biotechnology and pharmaceutical industries, the academic milieu, and government. The board plays an active role at both corporate and strategic levels, providing guidance and support to NEOMED’s experienced management team. These appointments raise the number of NEOMED board members to 11.

ABOUT NEOMED AND THE NEOMED INSTITUTENEOMED is a not-for-profit organization whose mission is to foster the development of promising therapeutic approaches emerging from academia and biotechnology companies. Created in 2012, NEOMED supports the development of projects up to the stage ofhuman proof of concept. NEOMED operates in a virtual mode using the services of theNEOMED Institute. The Institute is an open-access drug discovery hub with two high-tech research and development facilities; one in Technoparc Montréal’s Saint-Laurent Campus, specializing in small molecule therapeutics, and the other facility, NEOMED’s biologics and vaccine division, is located in Laval.NEOMED is jointly funded by the pharmaceutical industry, the Ministère de l’Économie,de l’Innovation et des Exportations du Québec, and the Networks of Centres of Excellence (NCE) of Canada. For more information, please visit our website: www.neomed.ca.